Some things scientists did back in the day seem primitive or ignorant now
Comparative metabolic effects of GLP-1 vs dual-agonist therapies
CLINICAL TRIAL EVIDENCE FOR GLP-1 RAs IN MASH Table 2 provides a summary of phase 2 and phase 3 studies examining GLP-1 RAs and dual or triple agonists (aiming glucagon, GIP, and GLP-1 receptors) in individuals with MASLD/MASH, where hepatic biopsies were used to evaluate liver outcomes [3,5,10,11,15,22-25,44-52]
WeightWatchers stock is down more than 88% since the beginning of the year
These critical modifications confer a slightly higher affinity to the GLP-1 receptor for both peptides, enabling lower concentrations to achieve equivalent receptor occupancy compared to native GLP-1 [13]
Fatigue is another experience some researchers report, similar to what is documented in the tirzepatide fatigue guide